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0.431(HAMD-17), -0.224(PCS), -0.650(MCS) -all p0.001-. Differences in CUDOS
scores between severity levels were found (p0.03-Bonferroni correction-). The
ability of CUDOS for predicting remission was adequate (AUC 0.837; CI 0.740-
0.934; p0.001. A cut-off point (CUDOS 24) was estimated (sensitivity0.81, spec-
ificity 0.77). CONCLUSIONS: The Spanish version of the CUDOS is a reliable and
valid measure of depression which can detect MDD patients with a suboptimal
response and be easily used during clinical practice in Primary Care.
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OBJECTIVES: To identify symptoms and functional impacts associated with major
depressive disorder (MDD) using concept elicitation interviews with patients to
determine relevant concepts for assessment in patient-reported outcome (PRO)
measures.METHODS:Qualitative interviews were conducted at 6 U.S. clinical sites
for cross-sectional assessment in a sample of adults (18-65 years) meeting DSM-
IV-TR criteria for MDD with a depressive episode within the last 6 months and
HAM-D score 18 at screening. Semi-structured individual interviews conducted
by trained research staff used open-ended questions and day-reconstruction exer-
cises to elicit spontaneous reports of symptom/impact concepts. Subsequent prob-
ing was used to assess concepts not spontaneously reported by subjects. Inter-
views were audio-recorded and transcribed. Transcripts were coded and analyzed
using Atlas.ti and summarized by like-content. Interview guide notations were
used to tag concepts offered by either spontaneous or probed report. RESULTS: A
total of 40 interviews were conducted with subjects (mean age: 46.211.8; 67.5%
female) representing a broad range of demographic characteristics. Saturation of
concepts was achieved within the first 32 interviews. Symptoms identified by the
majority of subjects included: Sadness (80.0% of subjects overall [and 52.5% spon-
taneously]), Tiredness (75.0[65.0]), Anger (72.5[57.5]), Loneliness (70.0[45.0]), Diffi-
culty Falling Asleep (67.5[55.0]), Low Self-Esteem (65.0[32.5]), Anxiety (62.5[55.0]),
Guilt (62.5[42.5]), Trouble Focusing (60.0[42.5]), Difficulty Waking (60.0[35.0]), Fa-
tigue (57.5[50.0]) and Irritability (57.5[42.5]). The most frequently reported impacts
were: Having Fewer Friends (92.5[65.0]), Feeling Isolated (82.5[57.5]), Dropping Daily
Activities (82.5[55.0]), Difficulty with Chores (77.5[30.0]), Interpersonal Difficulties
(72.5[37.5]), Workplace Difficulties (65.0[52.5]) and Neglecting Self-Hygiene
(65.0[17.5]). CONCLUSIONS: Symptoms and functional impacts associated with
MDD were identified through qualitative interviews. Relevant patient-identified
concepts should be considered in the development of patient-reported outcomes.
Concepts reported spontaneously provide good support for relevance, whereas
other concepts identified primarily through probing may not offer the best candi-
dates for assessment. Strength of these findings is suggested by achievement of
concept saturation.
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OBJECTIVES: To identify ways patients describe Major Depressive Disorder (MDD)
symptoms and impacts so new patient-reported outcome (PRO) measures can ef-
fectively incorporate the patient’s voice and perspective. METHODS: Qualitative
interviews were conducted with adult MDD patients (18-65 years) recruited from 6
US clinical sites. Patients were required at screening to have a Hamilton Depression
Rating Scale (HAM-D) score of18 and suffer depression within the past 6 months.
Individual interviews conducted by trained researchers used a semi-structured
interview guide designed to elicit responses about MDD symptoms and related
impacts. Interviews were audio-recorded, transcribed, cataloged and organized
into a coding framework using Atlas.ti software for content analysis. RESULTS:
Forty interviews were conducted. Mean age of participants was 46.2 (SD11.8);
67.5% were female, and 45.0% described their race as white. Saturation of concepts
was achieved within the first 32 interviews. A total of 3022 symptom and 830
impact code stems were derived from the transcripts. Eleven different domains
were developed in the coding framework for symptoms. Domains with the greatest
number of symptom expressions included Emotions/Mood (624/3022 [20.6%] of
expressions), Anxiety (398/3022 [13.2%]), and Cognition (358/3022 [11.8%]). Four dif-
ferent impact domains were identified, with Difficulty with Daily Activities (340/
830 [41.0%]) and Social/Relationship Changes (319/830 [38.4%]) receiving the great-
est number of expressions. A variety of different descriptions were used to
communicate these domains and sub-domains; representative quotations will be
presented. CONCLUSIONS: A broad range of concepts and terminology is used by
patients to describe the symptoms and impacts associated with their depression.
Participants identified symptoms that included both expected (based on diagnostic
criteria) and those not commonly described as core symptoms of MDD. Organiza-
tion of quotations into a coding framework and dictionary allows for the selection
of concepts and incorporation of the most meaningful patient language into early
stages of PRO instrument development.
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OBJECTIVES: Dysuria, xerostomia, anxiety and depression after initiation of treat-
ment with inhaled medicine have not been fully evaluated. The aim of this study
was to investigate the impact of treatment with inhaled drugs on these symptoms.
METHODS: This was a multicenter, prospective study conducted in 3 respiratory
clinics in Korea. The symptoms of dysuria, xerostomia, anxiety and depression
were observed via the International Prostate Symptoms Score (IPSS), Xerostomia
questionnaire (XQ), Hospital Anxiety & Depression Scale (HADS) at the baseline, 4
weeks, 12 weeks after initiation of inhalation therapy. The patients were divided
into two subgroups according to inhaler medication (: combination of inhaled
corticosteroids (ICS) and Long-acting 2-agonist (LABA) II: Long-acting muscarinic
antagonist (LAMA)). RESULTS: Among 90 patients enrolled, 84 patients were ana-
lyzed. After initiation of treatment with inhaled drugs, IPSS and XQ were not
changed significantly (IPSS, 11.969.85, 12.98 9.88, 13.85 0.08; XQ, 8.92 10.96,
10.31  11.33, 11.42  12.82 in the baseline, 4 weeks, 12 weeks respectively). HADS
at 12 weeks were significantly higher than that in the baseline. (p0.037) (9.61 
5.18, 10.36 6.07, 10.85  6.27 in the baseline, 4 weeks, 12 weeks respectively).
CONCLUSIONS: This study results indicate that Inhaler adversely affected dysuria,
xerostomia, anxiety and depression in new inhaler uses. But those differences
were not statistically significant except HADS. And further large sample size study
is needed.
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OBJECTIVES: 1) to identify concepts relevant to patients when measuring cognitive
symptoms of depression and their impacts, and 2) to adapt an existing patient-
reported measure of cognitive function for MDD. METHODS: Four age-stratified
focus groups (total N  33) were conducted with adults under treatment for MDD.
Following open concept elicitation, participants provided feedback on two self-
report measures of cognitive symptoms: the Applied Cognition General Concerns
Scale (Gerson et al., 2006) and the Perceived Deficits Questionnaire (PDQ) (Sullivan
et al., 1990). Focus group results led to a modified PDQ for MDD. Two sets of cogni-
tive interviews with additional MDD patients (N  17) refined the instrument,
resulting in the PDQ for Depression (PDQ-D). RESULTS: Focus group participants
reported seven different categories of cognitive symptoms. Across the age strata,
the most bothersome were difficulties with concentration, attention and memory.
Patients described many ways their cognitive symptoms affected them; productiv-
ity limitations were among the most salient. While most focus group participants
deemed the PDQ content appropriate, a shorter reference period and more explicit
response options were suggested. Cognitive interview results suggested that the
initial version of the 20-item PDQ-D was an appropriate and comprehensive as-
sessment of cognitive symptoms of MDD. Interview participants found the items
easy to understand and answer. Minor modifications made in early interviews
facilitated completion of the measure in later interviews. CONCLUSIONS: The
PDQ-D is a patient-reported assessment of cognitive function with potential to
provide unique information important for comprehensive evaluation of individual
patients with MDD and new treatments for this disorder.
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OBJECTIVES: To model the longitudinal latent effect on self-reported changes in
sleep disturbances and disability of adding pregabalin (PGB) to the usual care (UC)
therapy of outpatients with GAD treated in routine (Real World) clinical practice.
METHODS: A post-hoc analysis was performed using refractory outpatients with
GAD enrolled in a 6-month, prospective study carried-out in psychiatric clinics.
Anxiety symptoms, self-reported sleep disturbances and disability changes at end-
of-trial visit were assessed with the Hamilton-Anxiety (HAM-A), MOS-sleep and
WHO-DAS-II scales, respectively. Adding PGB to the UC was compared to UC alone
and its direct and indirect effects (expressed in percentages as the total effect
explained by the model) were estimated by means of a conditional latent curve
model applying structural equation modeling, with treatment as exogenous vari-
able, and anxiety as covariates. RESULTS: A total of 1546 (68% women, mean age;
45.5 years) PGB naïve patients were included in the analysis. Either symptoms of
anxiety, sleep disturbances or disability scores were significantly improved at end-
of-trial, with higher scores reduction in the cohort adding PGB: -15.92 vs. -14.48 in
HAM-A (F4.9, p0.027), -29.67 vs. -23.98 in MOS-sleep (F16.3, p0.001), and
A341V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
